- Home
- ATXS vs GAIN Comparison
ATXS vs GAIN Comparison
Compare ATXS & GAIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATXS
- GAIN
- Stock Information
- Founded
- ATXS 2008
- GAIN 2005
- Country
- ATXS United States
- GAIN United States
- Employees
- ATXS N/A
- GAIN N/A
- Industry
- ATXS Biotechnology: Pharmaceutical Preparations
- GAIN Finance: Consumer Services
- Sector
- ATXS Health Care
- GAIN Finance
- Exchange
- ATXS Nasdaq
- GAIN Nasdaq
- Market Cap
- ATXS 676.1M
- GAIN 551.1M
- IPO Year
- ATXS 2015
- GAIN 2005
- Fundamental
- Price
- ATXS $12.50
- GAIN $13.71
- Analyst Decision
- ATXS Hold
- GAIN Strong Buy
- Analyst Count
- ATXS 6
- GAIN 1
- Target Price
- ATXS $24.33
- GAIN $14.50
- AVG Volume (30 Days)
- ATXS 936.9K
- GAIN 127.1K
- Earning Date
- ATXS 11-12-2025
- GAIN 11-04-2025
- Dividend Yield
- ATXS N/A
- GAIN 16.16%
- EPS Growth
- ATXS N/A
- GAIN 135.24
- EPS
- ATXS N/A
- GAIN 2.49
- Revenue
- ATXS $706,000.00
- GAIN $97,742,000.00
- Revenue This Year
- ATXS N/A
- GAIN $6.54
- Revenue Next Year
- ATXS N/A
- GAIN $4.49
- P/E Ratio
- ATXS N/A
- GAIN $5.49
- Revenue Growth
- ATXS N/A
- GAIN 6.86
- 52 Week Low
- ATXS $3.56
- GAIN $11.42
- 52 Week High
- ATXS $12.72
- GAIN $15.34
- Technical
- Relative Strength Index (RSI)
- ATXS 67.29
- GAIN 45.43
- Support Level
- ATXS $12.31
- GAIN $13.52
- Resistance Level
- ATXS $12.62
- GAIN $13.75
- Average True Range (ATR)
- ATXS 0.23
- GAIN 0.22
- MACD
- ATXS -0.17
- GAIN -0.03
- Stochastic Oscillator
- ATXS 72.73
- GAIN 34.71
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
About GAIN Gladstone Investment Corporation Business Development Company
Gladstone Investment Corp operates as an externally managed, closed-end, non-diversified management investment company. Its objective is to invest in debt and equity securities of established private businesses operating in the U.S. and to achieve and grow current income by investing in debt securities of established businesses; provide the stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses. It focuses on investing in lower-middle-market private businesses.